drugset / Trial / NCT06000917
A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
Phase 2
Recruiting
62 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.
Timeline
- Start
- 2023-05-11
- Primary completion
- 2025-05-11
- Completion
- 2028-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Pyrotinib | Small molecule | 320 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |